circulating tumor DNA
Artemis DNA to Provide Datar Cancer Genetics Liquid Biopsy Tests in the US, Vietnam Under $250M Deal
Under the five-year exclusive agreement, Artemis DNA will offer Datar Cancer Genetics' Trucheck Pragma and Cancertrack tests in the US and Vietnam.
Having officially launched its Shield colorectal cancer screening assay as an LDT, Guardant stands to benefit from a head start in clinical establishment.
Delfi Diagnostics Begins Second, Larger Prospective Lung Cancer Screening Trial
The trial will pair a liquid biopsy screen with conventional low-dose CT scan screening for 15,000 patients at high risk for lung cancer.
The firm shared performance study results at a recent meeting and said it has begun processing samples for its first major pharma customer.
Proof-of-Principle Study Points to Possibility of Monitoring Pediatric ALL With Plasma Samples
Capture-based blood plasma sequencing helped track disease persistence or relapse and identify microbes that may cause infection in the immunosuppressed patients.
Apr 13, 2022
Apr 7, 2022
Feb 17, 2022
Dec 17, 2021
Nov 4, 2021
Guardant Health Q3 Revenues Up 27 Percent
Aug 5, 2021